ArticleMolecular and cellular biochemistry2019
Overexpression of ARNT2 is associated with decreased cell proliferation and better prognosis in gastric cancer.
Article in Molecular and cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Aryl hydrocarbon receptor nuclear translocator 2: a forgotten per-ARNT-Sim transcription factor.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
- Hypoxia-inducible factors: Regulatory functions and status as a therapeutic target in gastric cancer (Review).Oncology letters · 2026Review
- ARNT2 repression disrupts neuronal identity and promotes glioblastoma growth.Cell communication and signaling : CCS · 2026Article
- A data-driven pan-cancer proteogenomic analysis reveals the characteristics of human cancer protein expression.iScience · 2026Article
- Pan-cancer analysis of ARNT2 and its oncogenic role in cervical cancer.Journal of gynecologic oncology · 2025Article
- ARNT2-driven transcriptional activation of STRA6 reprograms fatty acid metabolism to promote retroperitoneal liposarcoma progression.Journal of cancer research and clinical oncology · 2025Article
- Article
- Novel Heredity Basis of the Four-Horn Phenotype in Sheep Using Genome-Wide Sequence Data.Animals : an open access journal from MDPI · 2023Article
- Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation.Breast cancer research and treatment · 2023Article
- Potential Molecular Mechanism of Upregulated Aryl Hydrocarbon Receptor Nuclear Translocator 2 in Nasopharyngeal Carcinoma.Computational and mathematical methods in medicine · 2022Article
- Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma.Journal of cellular and molecular medicine · 2021Article
- Genome Scale Modeling to Study the Metabolic Competition between Cells in the Tumor Microenvironment.Cancers · 2021Review
- Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer.Histology and histopathology · 2021Review
- Identification of a Novel Transcription Factor Prognostic Index for Breast Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Aryl hydrocarbon-receptor nuclear translocator (ARNT2) is a member of the bHLH PAS (basic helix-loop-helix Period/ARNT/Single-minded) family of transcription factors. Recently, some studies indicate that ARNT2 is associated with the occurrence and development of carcinoma. However, its roles in gastric cancer (GC) remain unclear. In the present study, we found that ARNT2 expression level is lower in GC tissues compared with adjacent non-tumor tissues, and negatively correlated with depth of invasion of the tumor, differentiated degree, and poor survival of GC patients. Overexpression of ARNT2 inhibits cell proliferation. Furthermore, AKT pathway contributed to ARNT2 -mediated PC proliferation. Taken together, our results provide the first evidence that high expression of ARNT2 inhibited proliferation of GC cells and affected tumor aggressiveness in GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.